4892 Stock Overview
Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cyfuse Biomedical K.K. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥697.00 |
| 52 Week High | JP¥1,490.00 |
| 52 Week Low | JP¥647.00 |
| Beta | 0 |
| 1 Month Change | -4.26% |
| 3 Month Change | -9.60% |
| 1 Year Change | -48.98% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.58% |
Recent News & Updates
Shareholder Returns
| 4892 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -0.1% | 1.0% | 1.8% |
| 1Y | -49.0% | -34.1% | 31.0% |
Return vs Industry: 4892 underperformed the JP Life Sciences industry which returned -34.1% over the past year.
Return vs Market: 4892 underperformed the JP Market which returned 31% over the past year.
Price Volatility
| 4892 volatility | |
|---|---|
| 4892 Average Weekly Movement | 8.3% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4892 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4892's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 21 | Shizuka Akieda | www.cyfusebio.com |
Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells.
Cyfuse Biomedical K.K. Fundamentals Summary
| 4892 fundamental statistics | |
|---|---|
| Market cap | JP¥5.53b |
| Earnings (TTM) | -JP¥589.00m |
| Revenue (TTM) | JP¥61.00m |
90.2x
P/S Ratio-9.3x
P/E RatioIs 4892 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4892 income statement (TTM) | |
|---|---|
| Revenue | JP¥61.00m |
| Cost of Revenue | JP¥23.00m |
| Gross Profit | JP¥38.00m |
| Other Expenses | JP¥627.00m |
| Earnings | -JP¥589.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -74.61 |
| Gross Margin | 62.30% |
| Net Profit Margin | -965.57% |
| Debt/Equity Ratio | 28.5% |
How did 4892 perform over the long term?
See historical performance and comparison